ID4 controls luminal lineage commitment in normal mammary epithelium and inhibits BRCA1 function in basal-like breast cancer. Issue 9 (September 2016)

• Record Type: Journal Article
• Authors: Baker, Laura A; Holliday, Holly; Swarbrick, Alexander
• Is Part Of: Endocrine-related cancer. Volume 23:Issue 9(2016)
• Page Start: R381
• Page End: R392
• Publication Date: 2016-09
• Subjects: basal-like breast cancer -- ID4 -- inhibitor of differentiation 4 -- BRCA1 -- lineage dependent oncogene; Endocrine glands -- Cancer -- Periodicals; Endocrinology -- Periodicals; Cancer -- Endocrine aspects -- Periodicals; 616.9944005
• DOI: 10.1530/ERC-16-0196
• Languages: English
• ISSNs: 1351-0088

Abstract

Abstract : Inhibitor of differentiation (ID) proteins are key regulators of development and tumorigenesis. One member of this family, ID4, controls lineage commitment during mammary gland development by acting upstream of key developmental pathways. Recent evidence suggests an emerging role for ID4 as a lineage-dependent proto-oncogene that is overexpressed and amplified in a subset of basal-like breast cancers (BLBCs), conferring poor prognosis. Several lines of evidence suggest ID4 may suppress BRCA1 function in BLBC and in doing so, define a subset of BLBC patients who may respond to therapies traditionally used in BRCA1 -mutant cancers. This review highlights recent advances in our understanding of the requirement for ID4 in mammary lineage commitment and the role for ID4 in BLBC. We address current shortfalls in this field and identify important areas of future research.